109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
木犀草素在骨质疏松症及骨代谢紊乱管理中的潜力：临床前研究见解
Authors Du J, Qin W , Wen F, Zhao D, Yin X, Guo Z, Feng Q, Gu E, Pan Z, Wang L
Received 14 June 2025
Accepted for publication 11 October 2025
Published 29 October 2025 Volume 2025:19 Pages 9715—9732
DOI https://doi.org/10.2147/DDDT.S547141
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Muzammal Hussain
Jianqiang Du,1,2,* Wenxiu Qin,2,* Fayan Wen,3,* Dan Zhao,3 Xuesong Yin,3 Ziyu Guo,2 Qijing Feng,1 Enpeng Gu,1 Zhicheng Pan,4 Linjue Wang1
1Department of Orthopedics, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 3Graduate School, Gansu University of Traditional Chinese Medicine, Lanzhou, People’s Republic of China; 4Department of Orthopedics, Binhai New Area Hospital of Traditional Chinese Medicine and the Fourth Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Linjue Wang, Email efyyx111@163.com Zhicheng Pan, Email 2286819448@qq.com
Abstract: Bone homeostasis is a process of dynamic regulation between bone resorption and bone formation, and is the foundation for normal skeletal development in the human body. Once this balance is disrupted, it will lead to bone loss and decreased bone density, profoundly affecting the occurrence and development of bone metabolism-related diseases. For example, common clinical bone metabolic disorders such as osteoporosis, avascular necrosis of the femoral head, and alveolar bone resorption. However, current treatments for bone metabolism-related diseases often have certain limitations, which has driven the development of complementary medicine that helps maintain bone health. Luteolin is a natural flavonoid compound renowned for its exceptional medicinal value and is often used to treat various diseases. In vitro studies indicate that luteolin not only protects osteoblast activity and promotes their osteogenic differentiation, but also inhibits osteoclast activation and their bone resorption function. Simultaneously, it regulates the osteogenic-adipogenic differentiation capacity of bone marrow mesenchymal stem cells, thereby promoting bone formation. Furthermore, Furthermore, in vivo studies indicate that luteolin significantly enhances parameters such as bone mass, trabecular thickness, and density in animal models of bone metabolic disorders, thereby promoting bone remodeling. In terms of mechanisms, luteolin may regulate signaling pathways related to bone metabolism, such as the PI3K/Akt, Wnt, RANKL/RANK/OPG, Nrf2, ERK and JAK/STAT pathways, to inhibit oxidative stress, reduce inflammatory responses, regulate cell death, and modulate the immune microenvironment. Additionally, we explored the pharmacokinetics of luteolin and the current status of drug delivery systems, including luteolin-loaded nanoparticles, biomimetic hydrogels, and porous scaffolds. These systems have effectively achieved controlled release of luteolin, providing drug delivery solutions with clinical translation potential for bone defect repair. The above evidence provides a solid foundation for future applications in bone metabolic homeostasis management and treatment based on luteolin.
Keywords: luteolin, bone formation, bone resorption, cell model, animal model, molecular mechanism, pharmacokinetics
1Department of Orthopedics, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 3Graduate School, Gansu University of Traditional Chinese Medicine, Lanzhou, People’s Republic of China; 4Department of Orthopedics, Binhai New Area Hospital of Traditional Chinese Medicine and the Fourth Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Linjue Wang, Email efyyx111@163.com Zhicheng Pan, Email 2286819448@qq.com
Abstract: Bone homeostasis is a process of dynamic regulation between bone resorption and bone formation, and is the foundation for normal skeletal development in the human body. Once this balance is disrupted, it will lead to bone loss and decreased bone density, profoundly affecting the occurrence and development of bone metabolism-related diseases. For example, common clinical bone metabolic disorders such as osteoporosis, avascular necrosis of the femoral head, and alveolar bone resorption. However, current treatments for bone metabolism-related diseases often have certain limitations, which has driven the development of complementary medicine that helps maintain bone health. Luteolin is a natural flavonoid compound renowned for its exceptional medicinal value and is often used to treat various diseases. In vitro studies indicate that luteolin not only protects osteoblast activity and promotes their osteogenic differentiation, but also inhibits osteoclast activation and their bone resorption function. Simultaneously, it regulates the osteogenic-adipogenic differentiation capacity of bone marrow mesenchymal stem cells, thereby promoting bone formation. Furthermore, Furthermore, in vivo studies indicate that luteolin significantly enhances parameters such as bone mass, trabecular thickness, and density in animal models of bone metabolic disorders, thereby promoting bone remodeling. In terms of mechanisms, luteolin may regulate signaling pathways related to bone metabolism, such as the PI3K/Akt, Wnt, RANKL/RANK/OPG, Nrf2, ERK and JAK/STAT pathways, to inhibit oxidative stress, reduce inflammatory responses, regulate cell death, and modulate the immune microenvironment. Additionally, we explored the pharmacokinetics of luteolin and the current status of drug delivery systems, including luteolin-loaded nanoparticles, biomimetic hydrogels, and porous scaffolds. These systems have effectively achieved controlled release of luteolin, providing drug delivery solutions with clinical translation potential for bone defect repair. The above evidence provides a solid foundation for future applications in bone metabolic homeostasis management and treatment based on luteolin.
Keywords: luteolin, bone formation, bone resorption, cell model, animal model, molecular mechanism, pharmacokinetics